Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour

État Nombre total Résumé
En négociation 35 Non liées à l’oncologie : 22
Liées à l’oncologie : 13
Négociations envisagées 11 Non liées à l’oncologie : 6
Liées à l’oncologie : 5
Négociations terminées 812 Avec lettre d’intention : 703
Sans entente : 109
Négociations qui n’ont pas eu lieu 109

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Rystiggo UCB Canada Inc. Generalized myasthenia gravis (gMG)
Imfinzi AstraZeneca Canada Inc. in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment
Pemazyre Incyte Biosciences Canada Corporation For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.​
Vemlidy Gilead Sciences Canada Inc. chronic Hepatitis B virus
Spevigo Boehringer Ingelheim (Canada) Ltd. generalized pustular psoriasis (GPP)
Imdelltra Amgen Canada Inc. For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy
Fabhalta Novartis Pharmaceuticals Canada Inc. Paroxysmal nocturnal hemoglobinuria (PNH)

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
TheraSphere Y-90 Glass Micropheres Boston Scientific Corporation As selective internal radiation therapy (SIRT) for local tumor control of solitary tumors in patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC), including those with recurrent or unresectable HCC. In addition to HCC
Keytruda Merck Canada Inc. For the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
Vabysmo Hoffmann-La Roche Ltd. Retinal vein occlusion
Venclexta AbbVie Corporation In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Filra Jamp Pharma Corporation Multiple Indications
Gazyva Hoffmann-La Roche Ltd. In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Pexegra Jamp Pharma Corporation Febrile neutropenia in non-myeloid malignancies
Kymriah Novartis Pharmaceuticals Canada Inc. Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy
Livmarli Mirum Pharmaceuticals Inc. Alagille syndrome
Myalepta Medison Pharma Canada Inc. Leptin deficiency in lipodystrophy
Breyanzi Bristol Myers Squibb Canada Inc. Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory di
Padcev Pfizer Canada ULC In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Awiqli Novo Nordisk Canada Inc. Diabetes Mellitus, Type 2
Jardiance Boehringer Ingelheim (Canada) Ltd. Adjunct to standard of care therapy for the treatment of chronic heart failure in adults

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation
Ryaltris Bausch Health, Canada Inc. Seasonal allergic rhinitis